MAIA Biotechnology Inc. (MAIA)
MAIA trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2024-12-31, https://www.sec.gov/Archives/edgar/data/1878313/000095017025043190/0000950170-25-043190-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2024-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | MAIA on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Not reported by the screener |
| IPO year | 2022 |
| SEC CIK | 0001878313 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2024
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$23.3M |
| Operating income | -$17.0M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | $0 |
| Total assets | $10.2M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. "Based on the cost control measures implemented, the Company believes the substantial doubt to continue as a going concern for at least 12 months from the date these financial statements were issued is reasonably alleviated." | 10-Q 2026-11-09 |
| Cash and burn | $0 cash; operating cash flow -$6.3M a quarter. | Report 2026-09-30 |
| Shares outstanding | 61,750,308 (2026-11-09); 37,032,307 a year earlier; 14,213,511 three years earlier. | Cover page 2026-11-09 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the market | Latest 2026-05-14 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Grant Thornton LLP, Charlotte, North Carolina, United States | PCAOB Form AP 2026-03-25 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $996K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$7.2M | -$6.3M | $0 | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q2 2026 2026-06-30 | Not filed | -$7.9M | -$6.8M | $0 | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q1 2026 2026-03-31 | Not filed | -$6.4M | -$5.3M | $0 | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q4 2025 2025-12-31 | Not filed | -$3.6M | -$7.0M | $0 | No debt tags | Needs four quarters | 10-K 2026-03-23 |
| Q3 2025 2025-09-30 | Not filed | -$8.9M | -$3.5M | $0 | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q2 2025 2025-06-30 | Not filed | -$5.3M | -$4.1M | $0 | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q1 2025 2025-03-31 | Not filed | -$4.5M | -$4.2M | $0 | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q4 2024 2024-12-31 | Not filed | -$3.6M | -$3.9M | $0 | No debt tags | $0 | 10-K 2026-03-23 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-10-07 |
| Latest annual report | 10-K | 2026-03-23 |
| Latest quarterly / interim | 10-Q | 2026-11-09 |
| Latest current report | 8-K | 2026-10-06 |
| Latest proxy | DEFA14A | 2026-05-19 |
Source: SEC EDGAR submissions feed, 504 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -5.7% |
| 1 month | -13.8% |
| 3 months | -25.4% |
| Year to date | -34.6% |
| 1 year | -1.0% |
| From 52-week high | -66.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ACRV | Acrivon Therapeutics Inc. | $1.46 | +0.69% | $62.6M |
| LFVN | Lifevantage Corporation Common Stock (Delaware) | $4.77 | -4.02% | $60.5M |
| GOSS | Gossamer Bio Inc. | $10.98 | +0.09% | $67.2M |
| TENX | Tenax Therapeutics Inc. | $1.48 | -8.64% | $67.4M |
| FBIO | Fortress Biotech Inc. | $1.71 | -9.04% | $57.7M |
| ZYBT | Zhengye Biotechnology Holding Limited | $1.43 | -4.67% | $67.8M |
| BOLD | Boundless Bio Inc. | $2.41 | -3.60% | $56.9M |
| MNOV | Medicinova Inc | $1.34 | -3.94% | $68.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier